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Abstract
Evidence shows that drug-drug interactions can occur at the level of drug transporters such as the
organic anion transporting polypeptides (OATPs), a group of membrane solute carriers that mediate
the sodium-independent transport of a wide range of amphipathic organic compounds. The
polyspecific OATP1B1 is exclusively expressed at the basolateral membrane of hepatocytes and
mediates uptake of amphipathic organic compounds from blood into hepatocytes. Nuclear receptors
are ligand-activated transcription factors that play an important role in xenobiotic disposition and
human diseases. Quite a few nuclear receptor ligands interact with transport proteins.
A high-resolution three-dimensional structure is critical to understand the polyspecificity of
OATP1B1 to predict and prevent adverse drug-drug interactions. Unfortunately there are no crystal
structures of OATPs/Oatps available to date. Therefore, in this study we attempted to elucidate the
characteristics of the substrate binding site of OATP1B1 based on small molecules interacting with
it. First, we identified inhibitors of the OATP1B1 model substrate estradiol-17β-glucuronide from
about forty nuclear receptor ligands. Among them, GW1929, paclitaxel and troglitazone were strong
inhibitors, while 5α-androstane, 5α-androstane-3β, 17β-diol-17-hexahydrobenzoate and estradiol-3-
benzoate were weak inhibitors. Then, we selected 25 compounds and performed inhibition kinetic
studies to identify competitive inhibitors and determine their Ki values which ranged from
submicromolar to submillimolar. Finally, we performed CoMFA analysis on the identified
competitive inhibitors. The CoMFA results indicate that the substrate binding site of OATP1B1
consists of a large hydrophobic middle part with basic residues at both ends that could be very
important for substrate binding.
Keywords
OATP; CoMFA; drug-drug interaction; nuclear receptor
*Corresponding author. Tel.: +1 913 5880028; Fax: +1 913 5887501. E-mail address: bhagenbuch@kumc.edu (B. Hagenbuch).
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting
proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could
affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Pharmacol Res. Author manuscript; available in PMC 2010 July 1.
Published in final edited form as:














Severe adverse drug-drug interactions represent an increasing risk for patients taking several
drugs at the same time. There is convincing evidence that besides at the level of drug
metabolizing enzymes, drug-drug interactions also occur at the level of drug transporters. The
human liver is the major organ for the uptake, metabolism and excretion of numerous drugs
and other xenobiotics. The first step in hepatic clearance of such chemicals is the uptake of
these substances from blood into liver mediated by transporters located on the basolateral
membrane of hepatocytes. Organic anion transporting polypeptides (humans: OATPs; rodents:
Oatps) are a group of membrane solute carriers that mediate the sodium-independent transport
of a wide range of amphipathic organic compounds including numerous drugs and other
xenobiotics [1-3]. So far, eleven human OATPs have been identified [2,3]. The polyspecific
OATP1B1 is exclusively expressed at the basolateral membrane of hepatocytes [4-7] and is
important for drug uptake.
Nuclear receptors are important ligand-activated transcription factors that strongly affect
xenobiotic disposition. Furthermore, they are important drug targets for human diseases like
diabetes, obesity and cancer [8-11]. Nuclear receptors play important roles in the regulation of
gene expression for metabolism, conjungation and transport of endogenous and exogenous
compounds [12-14]. To exert their physiological effects, the ligands of nuclear receptors need
to enter their target cells and transport proteins play a role during this process. For instance,
the pregnane X receptor (PXR) ligand rifampicin [15,16] and the farnesoid X receptor (FXR)
ligand cholic acid [17,18] are transported by OATP1B1 and 1B3; the thyroid hormones
triiodothyronine (T3) and L-thyroxine (T4) are transported by OATP1 and OATP4 family
members [4,19-23]. Besides being transported directly, interactions of nuclear receptor ligands
with transporters could result in unexpected potentially adverse effects. Previous studies
showed that the peroxisome proliferator-activated receptor (PPAR) ligand troglitazone caused
intracellular accumulation of bile salts and subsequent liver damage due to its inhibition of the
canalicular bile salt export pump (BSEP) [24], and that the glucocorticoid receptor ligand
dexamethasone inhibited OATP1A2-mediated dehydroepiandrosterone sulfate transport [25].
We recently demonstrated that the PXR ligand clotrimazole inhibited OATP1B1-mediated
estradiol-17β-glucuronide transport, but stimulated OATP1B3-mediated estradiol-17β-
glucuronide transport [26].
Given that adverse drug-drug interactions can be a result of inhibition at the uptake transporter
level, there is a critical need to understand the polyspecificity of OATP1B1 to predict and
prevent such adverse effects. Due to the difficulty of isolating and crystallizing membrane
proteins, researchers attempted to elucidate the characteristics of the substrate binding sites of
OATPs/Oatps based on the information of interacting small molecules. Chang et al. [27] used
computational pharmacophore modeling to illuminate the key features for substrate interaction
with rat Oatp1a1 and human OATP1B1 transporters. Yarim et al. [28] applied a three-
dimensional quantitative structure-activity relationship (3D-QSAR) technique to obtain
structural information of the substrate binding site of Oatp1a5. In these studies, the substrates
used to derive theoretical models might bind to different sites as experimental evidence shows
that OATPs/Oatps [26,29,30] as well as other transporters [31,32] might have multiple
substrate/ligand recognition sites. A computational model derived from compounds binding
at the same site should be more reasonable and reliable. Therefore we decided to use
competitive inhibitors of the OATP1B1 model substrate estradiol-17β-glucuronide which bind
to the same site as the substrate to derive a model. From about forty nuclear receptor ligands
we identified inhibitors of OATP1B1-mediated transport, carried out kinetic studies to identify
the competitive inhibitors and calculated their Ki values. Finally, we performed comparative
molecular field analysis (CoMFA) on the identified competitive inhibitors to elucidate possible
binding mechanism between OATP1B1 and its ligands.
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2. Materials and methods
2.1. Chemicals and reagents
Radiolabeled [3H]estradiol-17β-glucuronide (39.8 Ci/mmol) was purchased from PerkinElmer
Life Sciences (Boston, MA). Nuclear receptor ligands were obtained from Sigma-Aldrich (St.
Louis, MO) and Steraloids Inc. (Newport, RI). Cell culture reagents were from Invitrogen
(Carlsbad, CA), fetal bovine serum from Hyclone (Logan, UT). The BCA protein assay kit
was from Pierce (Rockford, IL).
2.2. Cell culture and uptake experiments
The Chinese Hamster Ovary (CHO) stable cell line expressing human OATP1B1 was described
previously [26]. Wild-type CHO cells served as control. Cells were grown at 37 °C in a
humidified 5% CO2 atmosphere in Dulbecco’s Modified Eagle Medium (DMEM), containing
1 g/l D-glucose, 2 mM L-glutamine, 25 mM Hepes buffer and 110 mg/l sodium pyruvate,
supplemented with 10% FBS, 50 μg/ml L-proline, 100 U/ml penicillin and 100 μg/ml
streptomycin without (for wild-type cells) and with (for OATP1B1-expressing cells) 500 μg/
ml G418.
For uptake experiments CHO wild-type and OATP-expressing cells were plated at 40,000 cells/
well on 24-well plates and 48 h later medium was replaced with medium containing 5 mM Na-
butyrate to induce nonspecific gene expression [33]. After another 24 h in culture, cells were
used for uptake experiments. Cells were washed three times with 1 ml of pre-warmed uptake
buffer (116.4 mM NaCl, 5.3 mM KCl, 1 mM NaH2PO4, 0.8 mM MgSO4, 5.5 mM D-glucose
and 20 mM Hepes, pH adjusted to 7.4 with Trizma base) and uptake was started by adding 200
μl of uptake buffer containing 0.3 to 0.6 μCi/ml of the radiolabeled substrate in the presence
or absence of inhibitors. After 20 s, at previously determined initial linear rate conditions,
uptake was stopped by removing the uptake solution and washing the cells four times with 1
ml of ice-cold uptake buffer. The cells were then solubilized with 500 μl of 1% Triton X-100
and 300 μl of the lysate were used for liquid scintillation counting. The protein concentration
was determined from the rest using the BCA assay with bovine serum albumin as a standard.
2.3. Identification of competitive inhibitors and calculation of Ki values
First, inhibition screening experiments were performed with 1 μM estradiol-17β-glucuronide
(containing 0.4 μCi/ml [3H]estradiol-17β-glucuronide) in the absence and presence of two
different concentrations for each compound. To analyze whether the groups were different
from the control, one-way ANOVA was performed followed by the Bonferroni t-test with
SigmaStat 3.5 (Systat Software, Inc., San Jose, CA). The p value for statistical significance
was set to be < 0.05. Inhibitors were selected based on their structures and inhibition effects
and then kinetic studies were carried out using four different substrate concentrations in the
absence or presence of two inhibitor concentrations that were selected based on the results of
the first screening experiment. Inhibition models for each inhibitor were compared by corrected
Akaike’s Information Criterion (AICc) and the Ki values of competitive inhibitors were
determined by nonlinear regression fitting with the Enzyme Kinetics Module of SigmaPlot
9.01 (Systat Software, Inc., San Jose, CA).
2.4. Computational methods
2.4.1. Determination of substrate and inhibitor conformation and their structural
alignment—All molecules were constructed using Sybyl7.1 [34] and the initial
conformations were obtained by molecular mechanics optimization using the Tripos force field
and Gasteiger-Hückel charges [35], with an energy gradient convergence criterion of 0.001
kcal/mol and a distance-dependent dielectric constant of 1. First, systematic conformational
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search was performed for the model substrate estradiol-17β-glucuronide. The conformation
with lowest energy was selected and subjected to energy minimization until convergence. The
resulting conformation was chosen as the binding conformation for estradiol-17β-glucuronide.
The distance between the negative charge and the hydrophobic center was measured and was
employed as a distance constraint during the conformational search of OATP1B1 inhibitors.
After that, systematic conformational search was carried out on the structures of the 21
competitive inhibitors of estradiol-17β-glucuronide with the distance constraint mentioned
above. The conformation with lowest energy for each inhibitor was chosen for molecular
alignment.
For molecular alignment, estradiol-17β-glucuronide was used as a reference and the initial
alignment was obtained by aligning the molecules according to their pharmacophoric centers.
An initial CoMFA model was developed (method described in section 2.4.2) and outliers
(leave-one-out cross-validated prediction error of greater than 0.5 log unit) were subjected to
conformational adjustment by rotating the rotatable bonds. However, all these rotations were
confined within 10 kcal/mol to its lowest energy. The obtained alignment was further iteratively
refined by the CoMFA field-fit repositioning tool (all settings were left at their default value;
no external perturbations or scalings were employed in the field specification; iteration
terminated when subsequent field-fitting of outliers failed to further improve their cross-
validated prediction errors).
2.4.2. CoMFA—Steric and electrostatic field energies were probed by an sp3 carbon atom
and a +1 net charge atom, respectively. Steric and electrostatic interactions were calculated
using a Tripos force field with a distance-dependent dielectric constant at all intersections in
a regularly spaced (2 Å) grid. The minimum σ (column filtering) was set to 1.0 kcal/mol to
improve the signal-to-noise ratio by omitting those lattice points whose energy variation was
below this threshold. A cutoff of 30 kcal/mol was adopted, and the regression analysis was
carried out using the partial least-squares (PLS) method with region focusing to improve the
cross-validation correlation coefficient (q2). The final model was developed with the optimum
number of components equal to that yielding the highest q2.
3. Results and discussion
3.1. Identification of inhibitors of the model substrate estradiol-17β-glucuronide for
OATP1B1
Estradiol-17β-glucuronide is one of the typical and well characterized OATP1B1 substrates
which are amphipathic organic compounds containing hydrophobic and negatively charged
groups. To identify potential inhibitors of estradiol-17β-glucuronide, inhibition experiments
were performed for 39 compounds including 37 nuclear receptor ligands, the HMG-CoA
reductase inhibitor pravastatin and the anti-fungal agent fluconazole (Fig. 1). As shown in Fig.
1, estradiol-17β-glucuronide was strongly inhibited by PPAR ligands GW1929, WY-14643
and troglitazone, PXR ligands rifampicin and paclitaxel, and high concentration FXR ligand
chenodeoxycholic acid. Most bile acids (cholic acid, deoxycholic acid, dehydrocholic acid,
glycocholic acid, lithocholic acid and taurocholic acid) and fatty acids (9-cis retinoic acid, 13-
cis retinoic acid and all-trans retinoic acid) showed moderate inhibition, while some highly
hydrophobic compounds such as 5α-androstane, 5α-androstane-3β, 17β-diol-17-
hexahydrobenzoate and estradiol-3-benzoate were very weak inhibitors.
3.2. Inhibition type and Ki determination of OATP1B1 inhibitors by kinetic studies
Based on the result of the inhibition experiment, we selected 25 compounds that share some
structural similarity to the model substrate estradiol-17β-glucuronide. They all have
hydrophobic and charge/hydrogen bonding groups and their inhibition activities cover a wide
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range from strong to weak inhibition. The chemical structures of these 25 compounds together
with the model substrate estradiol-17β-glucuronide are shown in Fig. 2.
Inhibition kinetic studies were carried out for the selected 25 compounds. Their inhibition types
were determined by AICc method and the Ki values of competitive inhibitors were calculated
by nonlinear regression fitting with the Enzyme Kinetics Module of SigmaPlot. The results
are listed in Table 1. The Ki values for 5α-androstane-3β, 17β-diol-17-hexahydrobenzoate and
estradiol-3-benzoate could not be determined due to their low water solubility and extremely
weak inhibition effect. Ketoconazole and HS-1200 are noncompetitive and uncompetitive
inhibitors for estradiol-17β-glucuronide respectively, indicating that they bind at a different
site than the substrate. The remaining 21 compounds are competitive inhibitors for the model
substrate estradiol-17β-glucuronide and their Ki values range from submicromolar to
submillimolar. Most strikingly, estrone-3-sulfate (Ki = 0.2 μM) and estradiol (Ki = 3.3 μM)
were much stronger inhibitors than estradiol-3-benzoate (its inhibition effect being very weak,
Fig. 1A), indicating that a polar or charge group at position C3 of the steroid ring
(estradiol-17β-glucuronide, Fig. 2) is very important for their activity. Cholic acid has three
hydroxyl groups at positions C3, C7 and C12; chenodeoxycholic acid and deoxycholic acid
have two hydroxyl groups at positions C3, C7 and C3, C12, respectively, while lithocholic
acid has only one hydroxyl group at position C3 (Fig. 2). The inhibition potency for these bile
acids increased with decreasing number of hydroxyl groups which is reflected by Ki values for
cholic acid of 25.0 μM, for chenodeoxycholic acid of 3.4 μM, for deoxycholic acid of 3.2 μM
and for lithocholic acid of 1.2 μM. Dehydrocholic acid which contains three carbonyl groups
instead of three hydroxyl groups at positions C3, C7 and C12 showed similar inhibition activity
(Ki = 29.7 μM) as cholic acid. Therefore we conclude that polar groups at positions C7 and
C12 are unfavorable for bile acids in the interaction with OATP1B1. The inhibition activity of
glycocholic acid (Ki = 22.2 μM) was very close to that of cholic acid, suggesting that the chain
length at position C17 is not very critical for their interaction with the protein. However, when
the carboxyl group of glycocholic acid was replaced by a much stronger negatively charged
sulfonate group, the activity increased two-fold (taurocholic acid, Ki = 11.4 μM).
The inhibition activities of compounds are governed by their chemical structures. Some
properties of the ligand binding site of a protein could be estimated based on the structures and
activities of the ligands. Therefore, we went on to carry out a 3D-QSAR study for OATP1B1
with the 21 competitive inhibitors of the model substrate estradiol-17β-glucuronide.
3.3. CoMFA model
Seventeen of the 21 competitive inhibitors together with the substrate estradiol-17β-
glucuronide were used as training set for constructing a CoMFA model. Fig. 3 shows the
structural alignment of the 18 compounds in the training set. The remaining four compounds,
namely clotrimazole, fenofibrate, mevinolin and troglitazone, were used as test set for model
validation. They were weak (fenofibrate), moderate (clotrimazole and mevinolin) and strong
(troglitazone) OATP1B1 inhibitors.
PLS analysis was carried out and the result is summarized in Table 2. The cross-validated value
q2 is 0.615 with an optimal number of components of 3. The noncross-validation PLS analysis
with the optimal components of 3 revealed a conventional r2 of 0.966. The F value is 133.7
and the standard error is 0.164. The steric fields contribute 70.2% to the model’s information,
while the electrostatic fields represent the other 29.8%. The correlation between the predicted
activities and experimental activities for the 18 compounds in the training set is depicted in
Fig. 4. These results demonstrate that the predicted activities are in good agreement with the
experimental data and suggest that our CoMFA model is reliable.
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The stability and predictive ability of the CoMFA model were further verified using the 4 test
compounds clotrimazole, fenofibrate, mevinolin and troglitazone. The correlation between the
predicted and experimental results for these 4 compounds is depicted in Fig. 4 (shown as ▲).
The predictions were in good agreement with the experimental data with an r2 of 0.917.
Fig. 5 shows the CoMFA contour plots of steric and electrostatic fields. The model substrate
estradiol-17β-glucuronide and the inhibitor cholic acid are displayed to aid in visualization.
Detrimental and beneficial steric interactions are displayed in yellow and green contours, while
blue and red contours illustrate the regions of desirable positive and negative electrostatic
interactions. The steric contours are mainly located in the area of the hydrophobic steroid ring
(Fig. 5A). It seems that a bulky group in the C7 and C15 positions of the four-fused ring of the
steroids would enhance their inhibition activities. Due to the conjugation effect, the orientation
of the aromatic ring A of estrogen is different from that of the saturated ring A of bile acids.
In the area between these two rings, there is a sterically unfavorable region. We consider this
is the main reason why estradiol-3-benzoate shows very weak inhibition effect because the
bulky benzoyl group of estradiol-3-benzoate is supposed to be located in this sterically
unfavorable region. The negative CoMFA region is mainly located in the area where most
tested compounds contain a negatively charged group (Fig. 5B). Most strikingly, there is
another negative region near the C3 position of the steroid ring which indicates that a negatively
charged group in C3 position is favorable. This might explain why estrone-3-sulfate which
contains a negatively charged sulfate group in the C3 position, showed a very high activity.
On the contrary, QSAR analysis done by Yarim et al. [28] showed that the sulfate group of
estrone-3-sulfate diminished its affinity for Oatp1a5 because the region where the sulfate group
was located favored a positive charge. This might reflect the difference of the substrate binding
pockets of these two transporters as OATP1B1 shows 100-fold higher affinity for estrone-3-
sulfate (Km = 2.4 μM) [26] than Oatp1a5 (Km = 268 μM) [36].
3.4. Potential interaction mode between OATP1B1 and its ligands
Based on the structures and activities of the OATP1B1 inhibitors and the CoMFA result, we
propose a model for their interactions with the protein as shown in Fig. 6. A typical inhibitor/
substrate of OATP1B1 contains a hydrophobic center and a negatively charged center which
form hydrophobic and electrostatic interactions with the protein, respectively. Another
negatively charged or polar group on the hydrophobic center in the opposite direction of the
negatively charged center is important for ligand binding probably by forming a salt bridge or
a hydrogen bond with the protein. The hydrophobic center area is a large space where bulky
substitutions might be beneficial for inhibition activity.
4. Conclusion
In the present study, we determined the Ki values for 21 competitive inhibitors of the model
substrate estradiol-17β-glucuronide for OATP1B1 ranging from submicromolar to
submillimolar. Most of these compounds are nuclear receptor ligands and contain a
hydrophobic center and a negatively charged center. CoMFA analysis was carried out on the
substrate and competitive inhibitors to explore the structural requirement for inhibitors that
interact with OATP1B1 at the same site as the model substrate estradiol-17β-glucuronide.
CoMFA results show that besides the hydrophobic and negatively charged centers, another
negatively charged or polar group at the C3 position is very important for strong inhibition.
This suggests that both ends of this substrate binding site of OATP1B1 have positively charged
residues. The middle of the binding pocket is relatively large as it is a sterically favorable
region. The obtained information could be helpful to better understand the characteristics of
the substrate binding site of OATP1B1 and to predict novel inhibitors and thus potential new
substrates.
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Inhibition of OATP1B1-mediated estradiol-17β-glucuronide uptake by 37 nuclear receptor
ligands, the HMG-CoA reductase inhibitor pravastatin and the anti-fungal agent fluconazole.
(A) Androgen receptor (AR), constitutive androstane receptor (CAR) and glucocorticoid
receptor (GR) ligands. (B) Peroxisome proliferator-activated receptor (PPAR) ligands. (C)
Pregnane X receptor (PXR) ligands. (D) Farnesoid X receptor (FXR), retinoic acid receptor
(RAR) and retinoid X receptor (RXR) ligands together with pravastatin and fluconazole.
Uptake of 1 μM estradiol-17β-glucuronide (containing 0.4 μCi/ml [3H]estradiol-17β-
glucuronide) was measured at 37 °C for 20 s with OATP1B1-expressing and wild-type CHO
cells in the absence or presence of inhibitors. Values obtained with wild-type CHO cells were
subtracted from values obtained with OATP1B1-expressing CHO cells and are given as percent
of the control. Values are given as the mean ± SD of triplicate determinations; * p < 0.05.
Abbreviations: 5α-Androstane hexa: 5α-androstane-3β, 17β-diol 17-hexahydrobenzoate;
HETE: 8(S)-hydroxy-(5Z,9E,11Z,14Z)-eicosatetraenoic acid.
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Chemical structures of the model substrate estradiol-17β-glucuronide and 25 inhibitors. These
25 inhibitors were selected based on their structures which contain a hydrophobic center and
a negative charge/hydrogen bonding center as the model substrate, and their inhibition
activities cover a wide range from strong to weak inhibition.
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Structural alignment of the 18 compounds in training set. Hydrogen atoms were omitted for
clarity.
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Predicted activities versus experimental activities of 22 OATP1B1 compounds. ●, compounds
in the training set; ▲, compounds in the test set.
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CoMFA contour maps in combination with estradiol-17β-glucuronide (cyan) and cholic acid
(white). Heteroatoms were rendered according to their default CPK colors (O = red). (A) Steric
field distribution. Regions where increasing the molecular volume increases activity are in
green and regions where increasing the volume decreases the activity are in yellow. (B)
Electrostatic field distribution. Regions where increasing the positive charges increases activity
are in blue and regions where increasing the negative charges increases the activity are in red.
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Schematic representation of potential interaction mode between OATP1B1 and its inhibitors.
Gui et al. Page 17

























Gui et al. Page 18
Table 1
Ki values of competitive inhibitors of OATP1B1-mediated estradiol-17β-glucuronide transport.
No. Compound Ki (μM)
1 Estradiol-17β-glucuronide 5.9 ± 1.2*
2 5α-Androstane 374 ± 123
3 5α-Androstane-3β, 17β-diol-17-hexahydrobenzoate Undeterminable
4 Bezafibrate 45.2 ± 5.9
5 Chenodeoxycholic acid 3.4 ± 0.5
6 Cholic acid 25.0 ± 3.3
7 Clotrimazole 7.6 ± 1.9
8 Dehydrocholic acid 29.7 ± 5.7
9 Deoxycholic acid 3.2 ± 0.5
10 Estradiol 3.3 ± 0.6
11 Estradiol-3-benzoate Undeterminable
12 Estrone-3-sulfate 0.2 ± 0.02
13 Fenofibrate 105.2 ± 26.7
14 Glycocholic acid 22.2 ± 3.9
15 GW1929 0.3 ± 0.05
16 GW4064 32.4 ± 6.7
17 HS-1200 Uncompetitive
18 Ketoconazole Noncompetitive
19 Lithocholic acid 1.2 ± 0.2
20 Mevinolin 12.7 ± 1.9
21 Mifepristone 2.2 ± 0.3
22 Pravastatin 21.8 ± 3.6
23 Taurocholic acid 11.4 ± 3.2
24 Thyroxine 3.5 ± 0.7
25 Troglitazone 1.0 ± 0.18
26 WY-14643 1.6 ± 0.11
*
For estradiol-17β-glucuronide the Km value is given. Values are given as the mean ± SD.
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Table 2
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